Influenza virus-like particle containing two different subtypes of hemagglutinin confers protection in mice against lethal challenge with A/PR8 (H1N1) and A/HK (H3N2) viruses

Iranian Red Crescent Medical Journal

Volumn 15, Issue 1, 2012, Pages

  Rezaei, Farhad ^a   Mirshafiey, Abbas ^a   Shahmahmoodi, Shohreh ^a   Shoja, Zabihollah ^a   Ghavami, Nastaran ^a   Mokhtari Azad, Talat ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Influenza Vaccines; Orthomyxoviridae; Virus like particles

Indexed keywords

HEMAGGLUTININ; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOFLUORESCENCE TEST; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ULTRACENTRIFUGATION; VIRUS LIKE AGENT; WESTERN BLOTTING;

EID: 84872136627     PISSN: 20741804     EISSN: None     Source Type: Journal    
DOI: 10.5812/ircmj.6252     Document Type: Article

References (28)

1. Pushko P, Pearce MB, Ahmad A, Tretyakova I, Smith G, Belser JA, et al. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. Vaccine. 2011;29(35):5911-8.
2. Pushko P, Kort T, Nathan M, Pearce MB, Smith G, Tumpey TM. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine. 2010;28(30):4771-6.
3. Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine. 2007;25(19):3871-8.
4. Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One. 2008;3(1):e1501.
5. Nwe N, He Q, Damrongwatanapokin S, Du Q, Manopo I, Limlamthong Y, et al. Expression of hemagglutinin protein from the avian influenza virus H5N1 in a baculovirus/insect cell system significantly enhanced by suspension culture. BMC Microbiol. 2006;6:16.
6. Crawford J, Wilkinson B, Vosnesensky A, Smith G, Garcia M, Stone H, et al. Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes. Vaccine. 1999;17(18):2265-74.
7. Li GX, Tian ZJ, Yu H, Jin YY, Hou SH, Zhou YJ, et al. Fusion of C3d with hemagglutinin enhances protective immunity against swine influenza virus. Res Vet Sci. 2009;86(3):406-13.
8. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine. 2005;23(50):5751-9.
9. Perrone LA, Ahmad A, Veguilla V, Lu X, Smith G, Katz JM, et al. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol. 2009;83(11):5726-34.
10. Robertson JS, Engelhardt OG. Developing vaccines to combat pandemic influenza. Viruses. 2010;2(2):532-46.
11. Zimmer G. RNA replicons - a new approach for influenza virus immunoprophylaxis. Viruses. 2010;2(2):413-34.
12. Quan FS, Steinhauer D, Huang C, Ross TM, Compans RW, Kang SM. A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine. 2008;26(26):3352-61.
13. Wang K, Holtz KM, Anderson K, Chubet R, Mahmoud W, Cox MM. Expression and purification of an influenza hemagglutinin--one step closer to a recombinant protein-based influenza vaccine. Vaccine. 2006;24(12):2176-85.
14. Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W. A "universal" human influenza A vaccine. Virus Res. 2004;103(1-2):173-6.
15. Jin R, Lv Z, Chen Q, Quan Y, Zhang H, Li S, et al. Safety and immunogenicity of H5N1 influenza vaccine based on baculovirus surface display system of Bombyx mori. PLoS One. 2008;3(12):e3933.
16. Lee DH, Park JK, Lee YN, Song JM, Kang SM, Lee JB, et al. H9N2 avian influenza virus-like particle vaccine provides protective immunity and a strategy for the differentiation of infected from vaccinated animals. Vaccine. 2011;29(23):4003-7.
17. Mahmood K, Bright RA, Mytle N, Carter DM, Crevar CJ, Achenbach JE, et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine. 2008;26(42):5393-9.
18. Pushko P, Tumpey TM, Van Hoeven N, Belser JA, Robinson R, Nathan M, et al. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine. 2007;25(21):4283-90.
19. Quan FS, Huang C, Compans RW, Kang SM. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol. 2007;81(7):3514-24.
20. Gomez-Puertas P, Mena I, Castillo M, Vivo A, Perez-Pastrana E, Portela A. Efficient formation of influenza virus-like particles: dependence on the expression levels of viral proteins. J Gen Virol. 1999;80 (Pt 7):1635-45.
21. Gomez-Puertas P, Albo C, Perez-Pastrana E, Vivo A, Portela A. Influenza virus matrix protein is the major driving force in virus budding. J Virol. 2000;74(24):11538-47.
22. Epand RM, Epand RF. Thermal denaturation of influenza virus and its relationship to membrane fusion. Biochem J. 2002;365(Pt 3):841-8.
23. Tumpey TM, Renshaw M, Clements JD, Katz JM. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol. 2001;75(11):5141-50.
24. Bodewes R, Osterhaus AD, Rimmelzwaan GF. Targets for the induction of protective immunity against influenza a viruses. Viruses. 2010;2(1):166-88.
25. Haaheim LR, Madhun AS, Cox R. Pandemic influenza vaccines - the challenges. Viruses. 2009;1(3):1089-109.
26. Kumar S, Chusid MJ, Willoughby RE, Havens PL, Kehl SC, Ledeboer NA, et al. Epidemiologic Observations from Passive and Targeted Surveillance during the First Wave of the 2009 H1N1 Influenza Pandemic in Milwaukee, WI. Viruses. 2010;2(4):782-95.
27. Wen Z, Ye L, Gao Y, Pan L, Dong K, Bu Z, et al. Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge. Antiviral Res. 2009;84(3):215-24.
28. Pyo HM, Masic A, Woldeab N, Embury-Hyatt C, Lin L, Shin YK, et al. Pandemic H1N1 influenza virus-like particles are immunogenic and provide protective immunity to pigs. Vaccine. 2012;30(7):1297-304.